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L-Arginine supplementation accelerates renal fibrosis and short- Studies using therapeutic dietary l-arginine supple-
ens life span in experimental lupus nephritis. mentation in renal disease have shown inconsistent ef-
Background. Inducible, high-output nitric oxide (NO) pro- fects in renal disease, a phenomenon that likely reflectsduction has been identified as a central mediator of cell injury
the complexity of its endogenous metabolism [1–4]. Di-in immune-mediated renal disease. In acute anti-thy-1 glomeru-
etary intake of l-arginine is semi-essential [5, 6]. In rodentslonephritis prefeeding with the NO precursor l-arginine in-
creases mesangial cell injury and the subsequent fibrosis. The and humans, l-arginine synthesis primarily occurs in the
present study tested the hypothesis that l-arginine supplemen- proximal tubule of the kidney using the nonprotein amino
tation may also be detrimental in chronic, NO-mediated murine acid l-citrulline as precursor. Endogenous l-arginine pro-lupus nephritis.
duction is sufficient to maintain whole-body l-arginineMethods. Groups (N  18) of female MRL/lpr mice with
metabolic homeostasis under normal physiologic condi-lupus nephritis were fed the following diets: (1) normal protein
(22% casein); (2) normal protein and 1.0% l-arginine in the tions, but when turnover increases in growth, inflamma-
drinking water; (3) low protein (6% casein); (4) low protein tion or tissue repair dietary supply can become rate-
0.4% l-arginine; and (5) low protein  1.0% l-arginine. After
limiting for the l-arginine metabolizing pathways [4].40 days mouse survival, albuminuria, matrix accumulation, in-
l-Arginine is precursor for a number of molecules withflammatory cell infiltration, immunoglobulin G (IgG) deposi-
tion, expression of transforming growth factor-1 (TGF-1), diverse biologic roles. l-arginine is a precursor for the
fibronectin and plasminogen activator inhibitor-1 (PAI-1) mRNA generation of polyamines, l-proline and agmatine [7].
and protein, anti-DNA antibody titer, inducible nitric oxide Polyamines are essential for cell proliferation. l-proline
synthase (iNOS) mRNA expression, blood amino acid levels,
is a key collagen constituent and is therefore importantblood urea nitrogen (BUN) concentrations and blood and uri-
for matrix build up. Agmatine, generated in mammals vianary NOx (nitrite  nitrate) levels were assessed.
Results. l-Arginine supplementation increased mortality sig- the recently discovered l-arginine decarboxylase pathway,
nificantly (P  0.02). The death rate increased from 0% in the is a regulator of renal hemodynamics and glomerular
lowest to 50% in the highest l-arginine intake group (normal filtration [8]. Agmatine inhibits other l-arginine metabo-protein 1.0% l-arginine). l-Arginine administration increased
lizing pathways, including ornithine decarboxylase (ODC),albuminuria, renal matrix accumulation, TGF-1, fibronectin,
the key enzyme in polyamine production, and induciblePAI-1, blood l-arginine, l-citrulline, BUN and blood and urine
NOx levels, while protein restriction reduced these parameters. nitric oxide synthase (iNOS) in vivo and in vitro [9]. In
Renal cell infiltration and iNOS mRNA expression were de- addition, l-arginine is the substrate for nitric oxide (NO)
creased in the low protein group only. Anti-ds DNA-IgG and production via three NO synthases (NOS). NOS I (nNOS)renal IgG deposition were comparable in all groups
is expressed constitutively in neuronal cells, producesConclusions. Increasing l-arginine intake increases the se-
NO as neurotransmitter and when expressed in maculaverity of renal fibrosis and the likelihood of death in MRL/lpr
mice. The results appear to be at least in part mediated through densa cells regulates tubular-glomerular feedback. NOS III
enhanced cytotoxic NO generation via iNOS. The data suggest (eNOS) is constitutively expressed in endothelial cells,
that l-arginine restriction should be considered in human im- produces NO in small amounts and is a critical mediatormune-mediated renal diseases.
of vasodilation. Of interest in the current study is NOS II
(iNOS). When iNOS is induced, large, cytotoxic quantities
Key words: l-Arginine, nitric oxide, TGF-, fibrosis. of NO are generated. The generation of large amounts of
NO from l-arginine has been identified as a key injuriousReceived for publication April 27, 2002
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tubular necrosis, renal transplant rejection and lupus ne- hour dark/12-hour light cycle. Before starting the experi-
phritis of the MRL/lpr mouse strain [10–12]. In anti-thy-1 ments animals were fed a normal protein diet for at least
glomerulonephritis alterations in availability of the NO 2 weeks to allow equilibration.
substrate l-arginine have shown that increasing l-argi-
Diets and L-arginine supplementationnine intake during mesangial cell injury increases the in-
jury and the subsequent fibrotic response, while l-arginine A normal and a low protein diet were fed (Harlan
given after the injury phase reduces the fibrotic response Teklad Winkelmann, Borchen, Germany). The normal
[13, 14]. A number of other studies have shown that protein diet comprised 22% casein with an l-arginine
dietary l-arginine supplementation is antifibrotic in renal content of 0.85% (Teklad No. 86550) while the low pro-
models characterized by increased blood pressure and tein diet was 6% casein and 0.23% l-arginine (Teklad
impaired endothelial NO production [1, 7, 15–21]. No. 86551). The low protein diet was made isocaloric
The fact that l-arginine supplementation can either (14.6 J/g) by the addition of sucrose. Supplementation
worsen or improve disease depending on when it is given of dietary l-arginine intake was carried out by adding
raises the question of how increasing its intake will affect l-arginine to the drinking water.
renal diseases in which NO-mediated injury is chronic
and subsequent fibrotic tissue repair is progressive. To Experimental design
address this question, we employed the model of chronic,
Female 16-week-old MRL/lpr mice (18 per group)NO-mediated lupus nephritis in MRL/lpr mice. Our hy-
were started on the following diets: (1) normal protein;pothesis was that increasing l-arginine intake would in-
(2) normal protein and 1% l-arginine in the drinking wa-crease renal fibrosis and shorten life span in these mice.
ter; (3) low protein; (4) low protein and 0.4% l-arginineDietary modifications were started in 16-week-old ani-
in the drinking water to achieve a normal l-argininemals with established nephritis. Diets used were normal
intake; and (5) low protein and 1% l-arginine in theor low in protein with and without supplemental l-argi-
drinking water.nine (0.4% or 1%) given in the drinking water. Low-
Food and water intake, body weight, and animal sur-protein diet was included to restrict l-arginine intake in a
vival were monitored closely. Animals with a continuousclinically feasible manner. Mouse survival, autoantibody
weight loss and with the appearance of being terminallyproduction and renal deposition, NO synthesis, albumin-
ill were sacrificed. At 22 weeks of age, after 40 days ofuria, renal function and matrix deposition were analyzed
dietary modification, the experiment was terminated.after 40 days.
From the surviving animals and those sacrificed early, a
24-hour urine was collected for determination of albu-METHODS
minuria, and the histologic degree of renal fibrosis and
Materials the cortical mRNA and protein expression for trans-
If not otherwise indicated, materials, chemicals or forming growth factor-1 (TGF-1), fibronectin and
culture media were purchased from Sigma Chemical- plasminogen activator inhibitor-1 (PAI-1) were analyzed.
Aldrich Co. (Taufkirchen, Germany). TGF-1 is a key mediator and marker of renal matrix
expansion [24]. Fibronectin is a matrix protein and aAnimals
sensitive indicator of matrix production. PAI-1 is an im-
Female MRL/lpr mice were obtained from Jackson portant protease inhibitor and indicates the activity of
Laboratory (Bar Harbor, ME, USA). MRL/lpr mice suf- the matrix degrading system [25]. In addition, blood anti-
fer from a spontaneous systemic lupus erythematosis– double-strain (ds) DNA antibody titers and renal immu-
like syndrome with lymphadenopathy and massive auto- noglobulin G (IgG) deposition were measured as an indi-
antibody production resulting from a mutation of the
cator of the activity of the underlying lupus disease.
FAS apoptosis gene [22, 23]. Due to immune complex
Blood urea nitrogen (BUN) concentration served asdeposition, the animals develop progressive renal ne-
measure of renal function. To characterize endogenousphritis and insufficiency. In female mice the disease is
NO generation, renal iNOS mRNA, as well as blood andmore severe and progresses faster than in male animals.
urinary NOx (nitrite/nitrate) levels, were determined.The first histologic evidence of lupus nephritis is usually
found by about 10 weeks of age. By 16 weeks, proteinuric
Urine collection and albuminurialupus nephritis is established and, by 25 weeks, about
For urine collection, mice were housed in metabolic50% of the female mice have died [22].
cages for 24 hours before sacrifice. Albuminuria was mea-Animal care and treatment were conducted in confor-
sured chemically using 3,4,5,6 tetraphenol blue as pre-mity with the guidelines of the American Physiological
viously described [26]. Albuminuria is expressed as mgSociety and were approved by local authorities. Animals
were housed in a constant temperature room with a 12- protein/24 hours.
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Sacrifice (Ambion, Huntington, UK). Nucleic acids were immobi-
lized by ultraviolet irradiation. Membranes were pre-Animals were anesthetized with ether and blood was
hybridized using QuikHyp hybridization solution (Stra-drawn by cardiac ventricle puncture using a heparinized
tagene, Amsterdam, The Netherlands) and hybridizedsyringe. The kidneys were harvested following a midline
with DNA probes labeled with 32P-deoxycytidimine tri-abdominal incision. For histologic examination, cortical
phosphate (32P-dCTP) by random oligonucleotide prim-tissue was fixed in 10% neutral buffered formalin. For
ing (Redi Prime II, Amersham Pharmacia Biotech,RNA isolation, cortical tissue was homogenized in Tri-
Buckinghamshire, UK). The blots were washed in 2 zol reagent and stored at 70C. For protein mea-
standard sodium citrate (SSC), 0.1% sodium dodecylsurement, cortical tissue was sonicated and centrifuged
sulfate (SDS) at 65C for 15 minutes, and in 0.1  SSC,at 14,000 g for 5 minutes. Supernatants were stored at
0.1% SDS at room temperature for 20 minutes. Blots70C until further analysis.
were exposed to a Storage Phosphor Screen (Amersham
Light microscopy Pharmacia Biotech) and analyzed by an imaging densi-
tometer (Typhoon 8600; Amersham Pharmacia Biotech).Microscopic examinations were performed in a blinded
The density of the bands for glyceraldehyde-3-phosphatefashion on 3 m sections of paraffin-embedded tissues
dehydrogenase (GAPDH) mRNA was used to controlstained with periodic acid-Schiff (PAS). Glomerular ma-
for differences in the RNA amount loaded to each lane.trix accumulation was evaluated in 20 glomeruli from
For quantitation purposes, values were divided by theeach mouse by scoring the percentage of mesangial ma-
density of bands for GAPDH in the same lane.trix occupying each glomerulus: 0  0%, 1  25%, 2 
DNA probes were generated by a standard PCR tech-50%, 3  75%, and 4  100%. Tubulointerstitial matrix
nique using the following primer pairs: GAPDH, sense,deposition was assayed in 20 randomly selected cortical
CCATCTTCCAGGAGCGAGAT, antisense, GATGAareas per sample observed at 250 magnification using
CCTTGCCCACAGCCT; TGF-1, sense, GGTGGCAthe following scale: 0  normal, 1  lesions involving
GGCGAGAGCGCTGA, antisense, GGCATGGTAGless than 10% of cortical area, 2 lesions involving 10%
CCCTTGGGCT; fibronectin, sense, GGTCCAAATCGto 30%, 3  lesions involving 30% to 50%, and 4 
GTCATGTTCCCA, antisense, GCCCCAGGTCTGCGlesions involving more than 50%. The mean of each
GCAGTTGT; PAI-1, sense, CAGCATGTGGTCCAGanimal was used for further statistical analysis. In addi-
GCCTCCAAA, antisense, TGTGCCGCTCTCGTTCAtion, tubulointerstitial mononuclear cell infiltration, glo-
CCTCGATCT.merular and tubulointerstitial IgG deposition were scored
Expression of iNOS mRNA was not detectable usingsemiquantitatively as previously described [27] with mi-
Northern blot and was therefore analyzed by semiquanti-nor modifications: 0  absent, 1  mild, 2  moderate,
tative PCR using a multiplex iNOS specific relative PCR3  marked, and 4  severe. Renal IgG deposition was
kit (Ambion, Huntington, UK) according to manufac-analyzed using a primary rabbit anti-mouse IgG antibody
turer’s instructions. Briefly, iNOS gene expression wasand an APAAP staining kit according to the instructions
visualized after 29 PCR cycles using cyber green (Mo Biof the manufacturer (DakoCytomation, Hamburg, Ger-
Tec GmbH, Go¨ttingen, Germany) and compared to 18Smany).
rRNA expression as internal standard. Primers and com-
BUN and amino acid levels petitors for 18S rRNA PCR were used in a 2:8 ratio. Gene
expression was analyzed using Typhoon 8600 as imagingPlasma urea nitrogen (BUN) was measured spectro-
densitometer. The density of each iNOS band was dividedphotometrically in an enzyme-based assay. Plasma levels
by the density of the corresponding 18S rRNA band.of l-arginine and its endogenous metabolites, l-citrulline,
l-ornithine, and l-proline, were determined by a standard-
TGF-1, fibronectin, and PAI-1 enzyme-linkedized high-performance liquid chromatography (HPLC)
immunosorbent assay (ELISA)technique [28].
Protein content of these matrix proteins was measured
RNA preparation, Northern hybridization and in the supernatant of sonicated and centrifuged cortical
relative reverse transcription-polymerase chain tissue. TGF-1 content was measured after acid activa-
reaction (RT-PCR) tion using a commercially available kit (TGF-1 Duo
kit; R&D Systems, Wiesbaden, Germany) according toCortical total RNA was extracted by a guanidinium
the manufacturer’s instructions. Fibronectin and PAI-1isothiocyanate method using Trizol reagent according
content were measured with modified inhibitory ELISAto the manufacturer’s instructions. For Northern analy-
according to published methods [29]. Three samplessis, RNA was denatured using glyoxal and fractionated by
from each mouse were analyzed. Results are expressedelectrophoresis through a 1.8% agarose gel (20 g/lane)
and transferred to a positively charged nylon membrane using cortical wet weight as denominator.
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Table 1. l-Arginine intake, number of dead mice, and
cumulative hazard ratios for the probability of death in MRL/lpr
mice fed a normal protein (NP) or low protein (LP) diet with
or without 0.4% or 1% l-arginine in the drinking water
(0.4% Arg or 1.0% Arg)
l-Arginine intake Dead mice Hazard ratio
Group mg/day number (cumulative %)
LP 9.7	0.1 0/18 0
NP 31.4	6.4 4/18 25%
LP  0.4% Arg 36.2	4.0 2/18 11%
LP  1.0% Arg 73.6	6.4 5/18 33%
NP  1.0% Arg 102.8	1.9 9/18 61%
Exemplary data of the third experimental week are shown for l-arginine
intake. Death rate was calculated after 40 days of dietary modification. Cumula-
tive hazard ratios were estimated using Cox regression.
Renal hydroxyproline content
The occurrence of hydroxyproline is confined almost
exclusively to connective tissue collagen and, therefore,
was used as marker of renal collagen content. Renal
hydroxyproline content was determined as previously Fig. 1. Effect of L-arginine supplementation on survival of MRL/lpr
mice. Starting at 16 weeks of age, mice were fed a normal protein (NP)described using Ehrlich’s reagent on duplicate samples
or low protein diet (LP) with or without 0.4% or 1% l-arginine in the
[30]. Results are expressed using cortical wet weight as drinking water (Arg).
denominator.
NOx measurements
1:100 dilution in PBS with 0.05% Tween (PBS-T) forNitrite and nitrate are stable end products of NO and
6 hours followed by a goat-antimouse IgG peroxidaseserved as indicators of endogenous NO synthesis [3].
antibody in PBS-T. After 45 minutes’ incubation 3,3
,5,5
Plasma and urinary NOx levels were measured by the
tetramethylbenzidine (TBM) substrate was added andGriess reaction after nitrate reductase treatment [31].
optical density (OD) was determined on an automatedBriefly, blood plasma and urine samples were diluted in
plate reader (MRX II) at 380 mm.phosphate-buffered saline (PBS) and incubated at room
temperature in the presence of 0.05 mmol/L nicotin-
Statistical analysisamide adenine dinucleotide phosphate (NADPH) and
Data are expressed as mean 	 SEM. The relationship0.05 U nitrate reductase (Boehringer Mannheim Bio-
between l-arginine intake and survival as well as cumula-chemicals, Mannheim, Germany). After a 45-minute in-
tive hazard ratios were analyzed using Cox regressioncubation, proteins were precipitated with 70% zinc sul-
[33]. Statistical analysis between the groups was per-fate solution and samples were centrifuged at 14,000 g
formed by ANOVA (analysis of variance) and subse-for 5 minutes. Sample (100 L) was then mixed with
quent t-testing with Bonferroni correction for multiple100 L Griess reagent [0.05% N-(1-naphthyl) ethylene
comparison. A P value0.05 was considered significant.diamine dihydrochloride, 0.5% sulfanilamide in 45% gla-
cial acetic acid] in 96-well plates. After a 10-minute incu-
bation in the dark, absorbance was read at 546 nm in an RESULTS
automated plate reader (MRX II; Dynex Technologies,
L-arginine intake and survivalFrankfurt/Main, Germany). Standard samples were pre-
Food consumption and weight gain were not differentpared with sodium nitrate and were also treated with
between the experimental groups (data not shown). Asnitrate reductase.
shown in Table 1, a 10.6-fold increase in l-arginine intake
Plasma anti-dsDNA antibodies was seen from the low protein to the normal protein
plus 1% l-arginine group. Interestingly, when one looksPlasma anti-dsDNA antibodies were determined by
at the number of animals dead after 40 days of dietaryELISA as previously described [32]. Briefly, 96-well poly-
modification, a relationship between l-arginine intakesterone plates were coated with mouse dsDNA (Promega
and death rates is seen. Survival data for each groupGmbH, Mannheim, Germany) using Reacti-Bind DNA
over time are plotted in Figure 1. Striking differencescoating solution (Perbio Science GmbH, Bonn, Ger-
many). Plates were washed and plasma was added in a are seen. While none of the animals in the low protein,
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Fig. 2. Effect of increasing L-arginine intake on albuminuria (A) and
plasma blood urea nitrogen (BUN) concentrations (B) of MRL/lpr mice
after 40 days of treatment with a normal protein (NP) or low protein
(LP) diet with or without 0.4% or 1% L-arginine in the drinking water
(Arg). *P  0.05; **P  0.01 vs. NP; #P  0.05 vs. LP.
low l-arginine group died, nine out of 18, or 50%, of
the animals in the highest group, normal protein  1%
l-arginine, died. The relationship was further analyzed
using Cox regression, which has the advantage that it
can model multiple covariates and calculates hazard ra-
tios [33]. With these hazard ratios one can estimate the
relative risk of death with incremental increases in a
Fig. 3. Effect of L-arginine supplementation on glomerular (A), andvariable of interest. Because protein intake and l-argi- tubulointerstitial matrix accumulation (B) and renal mononuclear cell
nine intake are related, these two covariates were used infiltration (C ) in MRL/lpr mice fed a normal protein (NP) or low
protein (LP) diet with or without 0.4% or 1% L-arginine in the drinkingin the analysis. Cox regression analysis indicated that
water (Arg) for 40 days. *P  0.05; **P  0.01 vs. NP;the covariate protein intake did not contribute signifi- #P  0.05; ##P  0.01 vs. LP.
cantly to death (P  0.22), while l-arginine intake was
significantly related to the likelihood of death in lupus
mice (P 0.015). Furthermore, cumulative hazard ratios,
which take into account both time of death and number l-arginine, 1.0 	 0.3 mg/day, P  0.05 vs. low protein).
Plasma BUN levels showed a similar pattern (Fig. 2B)of dead animals, showed an increase in the probability
of death from 0% in the lowest to 62% in the highest (N  eight to nine animals per group). Low protein
feeding reduced BUN concentrations significantly froml-arginine intake group (normal protein  1% l-argi-
nine) (Table 1). 91 	 21 mg/dL in the normal protein group to 33 	
3 mg/dL in the low protein group (P  0.05). l-ArginineWe next investigated whether there was an association
between l-arginine intake and the severity of renal fi- supplementation resulted in increased BUN concentra-
tions (normal protein 1.0% l-arginine, 159	 59 mg/dL,brosis in the five groups of lupus mice.
P  NS vs. normal protein; low protein  0.4% l-argi-
Albuminuria and BUN nine, 57 	 23 mg/dL, P  NS vs. low protein; low
As shown in Figure 2A, l-arginine intake had distinct protein  1.0% l-arginine, 57 	 10 mg/dL, P  0.05 vs.
effects on 24-hour albumin excretion (N  15 to 18 low protein, respectively).
animals per group). In the normal protein group, albu-
Histologic examination: Renal matrix expansion andminuria was markedly higher in animals with l-arginine
mononuclear cell infiltrationthan in those without l-arginine in the drinking water
(8.9 	 2.7 mg/day vs. 4.5 	 1.0 mg/day), although, due Glomerular and tubulointerstitial matrix score was
high in lupus mice fed a normal protein diet and drinkingto high variation, the difference did not reach significance
(P  0.14). In contrast, feeding low protein diet signifi- tap water only (glomerular, 3.12 	 0.12; tubulointersti-
tial, 1.47 	 0.11) (Fig. 3 A and B). Feeding low proteincantly reduced albuminuria (0.3 	 0.1 mg/day, P  0.05
vs. normal protein). Adding 0.4% or 1% l-arginine to the diet limited renal matrix accumulation significantly (2.67	
0.17 and 0.77	 0.16, respectively, both P 0.01 vs. normaldrinking water in the low protein diet group augmented
urinary albumin excretion (low protein  0.4% l-argi- protein). In both diet groups, addition of l-arginine re-
sulted in significantly increased glomerular matrix depo-nine, 1.4 	 0.6 mg/day, P  0.06; low protein  1%
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tion (N  12 to 18 animals per group). In the normal
protein animals, l-arginine supplementation increased
cortical TGF-1 content from 182 	 8 to 236 	 11 pg/
100 mg wet weight (P  0.01) and in the low protein
group from 141 	 8 to 153 	 8 pg/100 mg wet weight
(low protein  0.4% l-arginine) and to 187 	 11 pg/
100 mg wet weight (low protein  1.0% l-arginine, P 
0.01), respectively. The difference between the normal
and low protein group without l-arginine supplementa-
tion was also significant (P  0.01). The cortical protein
expression of fibronectin and PAI-1 followed this profile,
although not always reaching statistical significance (Fig.
4 B and C) (N  12 to 18 animals per group). Renal
hydroxyproline content showed a similar pattern (Fig. 4D):
normal protein, 323 	 25 g/100 mg; normal protein 
1.0% l-arginine, 380 	 41 g/100 mg; low protein 304 	
34 g/100 mg; low protein  0.4% l-arginine, 351 	 25
g/100 mg; and low protein  1.0% l-arginine, 353 	
28 g/100 mg wet weight, respectively (six to eight ani-
mals per group, P  NS for all groups).
The relative cortical expression of TGF-1, fibronectin
and PAI-1 mRNA corrected for GAPDH is depicted in
Figure 5 (N  9 to 12 animals per group). Compared to
Fig. 4. Effect of L-arginine supplementation on renal protein expres- the normal protein animals drinking tap only, low protein
sion of transforming growth factor-1 (TGF-1) (A), fibronectin (B), diet significantly decreased TGF-1 mRNA expressionplasminogen activator inhibitor-1 (PAI-1) (C ) and hydroxyproline con-
from 1.13 	 0.12 to 0.53 	 0.06 (P  0.01). In both basictent (D). MRL/lpr mice (16 weeks old) were fed a normal protein (NP)
or low protein (LP) diet with or without 0.4% or 1% l-arginine in the diet groups, l-arginine feeding elevated TGF- mRNA
drinking water (Arg) for 40 days. *P  0.05; **P  0.01 vs. NP; #P  expression: normal protein  1.0% l-arginine, 1.40 	0.05; ##P  0.01 vs. LP.
0.20, P  0.28 vs. normal protein; low protein  0.4%
l-arginine, 1.35 	 0.14; low protein  1.0% l-arginine,
1.31 	 0.11, both P  0.01 vs. low protein, respectively.
Fibronectin expression showed the same pattern, al-sition (normal protein  1.0% l-arginine, 3.49 	 0.12,
P  0.05 vs. normal protein; low protein  0.4% l-argi- though the differences did not reach statistical signifi-
cance: normal protein, 0.89 	 0.20; normal protein nine, 3.26 	 0.14, P  0.05 vs. low protein; and low
protein  1.0% l-arginine, 3.33 	 0.13, P  0.01 vs. 1% l-arginine, 1.46 	 0.47; low protein, 0.46 	 0.13; low
protein 0.4% l-arginine, 0.64	 0.11; low protein 1%low protein, respectively) and tubulointerstitial matrix
deposition (normal protein 1.0% l-arginine, 1.81	 0.13, l-arginine, 0.95 	 0.25, respectively. More pronounced
changes were seen in PAI-1 mRNA expression. In ani-P  0.07 vs. normal protein; low protein  0.4% l-
arginine, 1.40	 0.19; and low protein 1.0% l-arginine, mals given low protein only, PAI-1 expression was sig-
nificantly reduced to 0.62	 0.08 compared to the normal1.45 	 0.17, both P  0.05 vs. low protein, respectively).
The degree of tubulointerstitial mononuclear cell infil- protein group value of 1.26	 0.18 (P 0.01). l-Arginine
feeding augmented PAI-1 mRNA expression in alltration was comparable in the normal protein and normal
protein  1% l-arginine mice (1.13 	 0.12 vs. 1.02 	 groups: normal protein  1.0% l-arginine, 1.40 	 0.23,
P  0.63 vs. normal protein; low protein  0.4% l-argi-0.12, P  NS, Fig. 3C). Low protein feeding decreased
cell infiltration significantly (0.64 	 0.13, P  0.05 vs. nine, 1.08 	 0.14, P  0.05 vs. low protein; and low
protein  1.0% l-arginine, 1.21 	 0.13, P  0.01 vs. lownormal protein), while addition of l-arginine to the low
protein diet increased cell infiltration to above normal protein, respectively.
Together the data on albuminuria, BUN, histologicprotein levels (low protein  0.4% l-arginine, 1.30 	
0.11 and low protein  1.0% l-arginine, 1.29 	 0.10, matrix accumulation, and expression of TGF-1, fibro-
nectin and PAI-1 consistently show that l-arginine inten-both P  0.01 vs. low protein).
sifies renal fibrosis, while the low protein, low l-arginine
Protein and mRNA expression of TGF-1, diet is beneficial. To further characterize the detrimental
fibronectin, and PAI-1 effects of l-arginine supplementation and the protective
effects of low protein diet, we analyzed blood aminoAs seen in Figure 4A, cortical TGF-1 content closely
followed the changes seen in histological matrix deposi- acid levels related to l-arginine metabolism, blood anti-
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Fig. 5. Representative Northern blot (A) and
effect of L-arginine supplementation on corti-
cal mRNA expression of transforming growth
factor-1 (TGF-1) (B), fibronectin (C ), and
plasminogen activator inhibitor-1 (PAI-1) (D)
in MRL/lpr mice fed a normal protein (NP)
or low protein (LP) diet with or without 0.4%
or 1% L-arginine in the drinking water (Arg).
Expression levels are corrected for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH)
expression. **P  0.01 vs. NP; #P  0.05; ##
P  0.01 vs. LP.
Table 2. Plasma levels of amino acids reflecting endogenous supplementation was associated with higher plasma l-argi-
l-arginine metabolism in MRL/lpr mice fed a normal protein (NP)
nine, l-ornithine, and l-proline concentrations, indicat-or low protein (LP) diet with or without 0.4% or 1% l-arginine in
the drinking water (0.4% Arg or 1.0% Arg) ing activated endogenous l-arginine metabolism. l-Citrul-
line levels, a marker of endogenous NOx generation,l-Arginine l-Citrulline l-Ornithine l-Proline
Group lmol/L lmol/L lmol/L lmol/L were significantly increased by l-arginine supplementa-
tion in both the normal and the low protein diet animalsNP 150	60 72	6 199	23 272	34
NP  1.0% Arg 174	29 78	8 239	33 337	21 (Table 2).
LP 154	37 51	1a 108	18a 177	26a
LP  0.4% Arg 166	23 64	8 133	23 194	11
Anti-dsDNA antibodies and renal IgG depositionLP  1.0% Arg 203	58 67	4b 222	98 224	49
a P  0.05 vs. NP; b P  0.01 vs. LP Anti-dsDNA antibody titers were measured by ELISA
and are expressed as relative OD (N  9 to 17 animals
per group). As shown in Figure 6A the OD differences
between the groups were minor and not statistically sig-dsDNA antibody titers, renal IgG deposition, expression
nificant: normal protein, 0.38 	 0.06; normal protein of iNOS and blood and urinary NOx levels.
1.0% l-arginine, 0.40 	 0.05; low protein, 0.34 	 0.05;
Amino acid levels low protein  0.4% l-arginine, 0.39 	 0.06; and low
protein  1.0% l-arginine, 0.38 	 0.04. As shown inIn comparison to the normal protein animals, feeding
Figure 6 B and C, renal deposition of mouse IgG deposi-a low protein diet significantly reduced plasma l-citrul-
tion in glomeruli and tubulointerstitium was not signifi-line, l-ornithine, and l-proline concentrations in nephritic
cantly different among the groups either.MRL/lpr mice, while l-arginine levels were comparable
(Table 2, N  five to six animals per group). l-Arginine These results indicate that the dietary modifications
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Fig. 6. Effect of increased L-arginine intake on plasma anti-dsDNA
antibody levels (A) and glomerular (B) and tubulointerstitial IgG depo- Fig. 7. Effect of L-arginine supplementation on cortical mRNA expres-
sition (C) in MRL/lpr mice fed a normal protein (NP) or low protein (LP) sion of inducible nitric oxide synthase (iNOS) (A), plasma (B), and
diet with or without 0.4% or 1% L-arginine in the drinking water (Arg). 24-hour urine levels (C ) of NOx (nitrate and nitrite) in MRL/lpr mice
fed a normal protein (NP) or low protein (LP) diet with or without
0.4% or 1% L-arginine in the drinking water (Arg). *P  0.05; **P 
0.01 vs. NP; #P  0.05; ##P  0.01 vs. LP.applied did not affect autoantibody production and renal
IgG deposition in the MRL/lpr lupus mice.
Renal iNOS expression, blood and urinary NOx levels
tion (plasma NOx low protein  0.4% l-arginine, 91 	
In the normal protein animals, iNOS mRNA expres- 12 nmol/mL, P  0.05 vs. low protein and low protein 
sion was comparable in the animals with and without 1.0% l-arginine, 96 	 6 nmol/mL, P  0.01 vs. low pro-
l-arginine supplementation (1.06	 0.15 and 0.79	 0.10) tein; urine NOx low protein  0.4% l-arginine, 1634 	
(Fig. 7A) (N seven to nine animals per group). Feeding 560 nmol/24 hours and low protein  1.0% l-arginine,
low protein diet significantly reduced iNOS expression 1366 	 486 nmol/24 hours).
(0.39 	 0.07, P  0.01 vs. normal protein). Adding
l-arginine to the drinking water resulted in a marked
DISCUSSIONincrease in iNOS expression (low protein  0.4% l-argi-
nine, 0.82	 0.12, P 0.05 vs. low protein; low protein In the present study, using MRL/lpr lupus mice, in-
creasing l-arginine intake resulted in more severe renal1.0% l-arginine, 1.06 	 0.14, P  0.01 vs. low protein,
respectively). In the normal protein group both plasma fibrosis, more severe renal insufficiency and markedly in-
creased mortality. In contrast, a low protein, low l-argi-and urinary levels of NOx were higher in the animals with
than in those without l-arginine supplementation (plasma nine diet prolonged survival in MRL/lupus mice, reduced
renal fibrosis and loss of renal function, suggesting thatNOx 102 	 7 vs. 82 	 7 nmol/mL, urine NOx 2122 	
260 vs. 1747 	 272 nmol/24 hours) (Fig. 7 B and C) (N low protein diet is beneficial in slowing the progression
of lupus nephritis. Further, it is interesting to note that9 to 14 animals per group). Consistent with the deceased
iNOS expression, low protein diet markedly reduced the protection conferred by low protein diet was com-
pletely reversed for most variables by supplementationplasma NOx levels (60	 5 nmol/mL, P 0.05 vs. normal
protein) as well as urinary NOx excretion (724 	 236 with l-arginine in drinking water. Thus, while animals
fed low protein had significantly fewer deaths, less matrixnmol, P  0.05 vs. normal protein). Similar to the iNOS
mRNA data, l-arginine supplementation in low protein deposition, lower TGF- and PAI-1 protein and mRNA,
and lower iNOS expression, simply adding l-arginine toanimals increased plasma NOx and urinary NOx excre-
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drinking water brought animals fed low protein diet back immune-mediated human renal diseases such as mes-
angioproliferative glomerulonephritis, including IgA ne-to levels for these disease measures that did not differ
from those seen in the normal protein group. These phropathy, Wegener’s granulomatosis, lupus nephritis,
and kidney transplant rejection [42–45]. In one study,findings strongly implicate low l-arginine as a key factor
in the protective effects of low protein diet in lupus mice. iNOS expression closely correlated with histologic signs
of renal damage and loss of renal function [42].The deleterious action of l-arginine supplementation
in MRL/lpr mice is consistent with our earlier study in On the other hand, data in a model of immune complex
glomerulonephritis, where iNOS expression and high-acute anti-thy-1 glomerulonephritis [13], in which pre-
feeding with l-arginine increased mesangial cell lysis and output NO production occurs, inhibiting NO synthesis
worsened disease. [46–49]. Other data suggest iNOS ex-the subsequent fibrotic response. Both models share in-
duction of iNOS as a key injurious stimulus, which is pression can be neutral. iNOS knockout mice showed
similar disease severity to wild-type mice when antiglo-transient in anti-thy-1 glomerulonephritis but chronic in
MRL/lpr mice [12, 13]. In addition, blockade of NOS has merular basement glomerulonephritis was induced [50].
The situation appears to be even more complex in experi-been shown to reduce fibrosis in both models [10, 12, 34].
The expression patterns of the markers of tissue repair mental kidney transplant rejection. Although specific
iNOS inhibition markedly reduced tubulointerstitial in-were similar in acute anti-thy-1 glomerulonephritis and
chronic MRL/lpr lupus nephritis following l-arginine ad- jury and improved graft function in a rat model of mild
allograft rejection, increasing dietary l-arginine intakeministration [13, 35]. Together these studies support the
notion that acute and chronic fibrotic renal diseases are was protective in the same model [51, 52].
The effect of l-arginine feeding on inflammatory cella continuum. Anti-thy-1 glomerulonephritis involves one
cycle of injury and repair, whereas lupus nephritis is a infiltration appears to vary with experimental model. In
experimental obstructive nephropathy and puromycin-model of repeated or continual cycles of NO-mediated
injury and subsequent repair. These cycles follow so induced nephrosis, l-arginine supplementation reduced
cell infiltration [17]. In contrast, in both this study and inclosely that resolution of pathologic matrix does not oc-
cur and the expansion of extracellular matrix progresses the early phase of anti-thy-1 glomerulonephritis, l-arginine
feeding did not alter cell infiltration in animals fed a[4, 12, 36].
The fact that iNOS levels were comparable in animals normal protein diet [13]. However, restricting protein in
MRL/lpr mice markedly limited renal cell infiltration.fed normal protein with and without l-arginine and that
l-arginine supplementation lead to higher blood and uri- That this was due to the low arginine content of low
protein diet is supported by the finding that adding onlynary NOx levels suggests that the detrimental effects of
l-arginine are at least in part mediated through greater l-arginine back to low protein diet completely restored
mononuclear cell infiltration to levels comparable tosubstrate availability for iNOS. This is consistent with
data showing that inducible NO production directly those seen with normal protein diet. Thus, while l-arginine
supplementation produces different results in differentcorrelates with the extracellular l-arginine supply in cul-
tured activated macrophages [37] and in nephritic glo- models, l-arginine restriction in the form of low protein
diet appears to dramatically reduce cell infiltration. Wemeruli [13]. The action of reducing dietary protein dra-
matically decreased iNOS expression and blood and have seen similar effects of protein restriction on cell infil-
tration in both anti-thy-1 glomerulonephritis and obstruc-urinary NOx levels, while simply adding back high l-argi-
nine to the diet lead to a complete rebound in these tive nephropathy (unpublished data).
High l-arginine intake has also been shown to reducemeasures to levels not significantly different from those
of mice fed normal protein diet. These data strongly the severity of a number of hypertensive renal diseases
presumably by enhancing deficient endothelial NO pro-suggest that a large component of the therapeutic effect
of low protein diet in lupus mice results from l-arginine duction [1, 7, 15–21]. Even in normotensive models such
as anti-thy-1 glomerulonephritis, l-arginine supplemen-restriction reducing NO-mediated tissue damage. The
mechanism underlying decreased iNOS expression with tation reduces the fibrotic response, if started after the
injury phase of disease [14]. The l-arginine metaboliteslow protein is entirely unclear, but since our dietary mod-
ifications did not alter autoantibody production and re- agmatine and NO have been implicated as mediators of
this pressure-independent action of l-arginine supple-nal deposition, the data point to an effect of low pro-
tein on disease severity downstream from autoantibody mentation [53] (abstract; Peters H, J Am Soc Nephrol
12:713A, 2001).production.
l-Arginine supplementation, iNOS induction and wors- The results of the present study are important for the
current and future use of l-arginine supplementation inened disease have been shown in models of immune-medi-
ated dermal vasculitis, hypoxic lung injury, toxic colitis, human disease. Dietary l-arginine supplementation has
shown some benefit in cardiovascular diseases, includingand brain reperfusion [4, 38–41]. Increased expression
of iNOS mRNA and protein has been documented in hypertension, heart failure, and coronary and peripheral
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